• 1. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 2. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 3. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 4. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 5. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341

Professional Introduction to 4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride (CAS No. 106261-49-8)

4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride, with the CAS number 106261-49-8, is a significant compound in the field of pharmaceutical chemistry and biochemistry. This compound belongs to the class of substituted benzoic acids, characterized by the presence of a piperazine moiety linked to a benzene ring. The dihydrochloride salt form enhances its solubility and stability, making it a valuable intermediate in the synthesis of various pharmacologically active molecules.

The< strong>4-Methylpiperazin-1-yl group is a crucial structural feature that imparts unique chemical and biological properties to this compound. Piperazine derivatives are widely recognized for their role as pharmacophores in drug design, particularly in the development of central nervous system (CNS) drugs, antihistamines, and antipsychotics. The methyl substitution at the 4-position of the piperazine ring influences its pharmacokinetic behavior, enhancing metabolic stability and reducing potential side effects associated with unsubstituted piperazine derivatives.

In recent years, there has been growing interest in the development of novel therapeutic agents targeting neurological disorders. The< strong>benzoic acid moiety in 4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride contributes to its potential as a scaffold for designing molecules with enhanced binding affinity and selectivity. Benzoic acid derivatives have been extensively studied for their anti-inflammatory, analgesic, and antioxidant properties, making this compound a promising candidate for further exploration in drug discovery.

One of the most compelling aspects of this compound is its versatility in medicinal chemistry. The presence of both the piperazine and benzoic acid moieties allows for diverse structural modifications, enabling researchers to fine-tune its pharmacological profile. For instance, modifications at the aromatic ring or the piperazine nitrogen can significantly alter its interaction with biological targets, leading to improved efficacy and reduced toxicity.

Recent studies have highlighted the potential of< strong>4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride as a lead compound for the development of new therapeutic agents. Researchers have demonstrated its efficacy in preclinical models for conditions such as depression, anxiety, and chronic pain. The compound's ability to modulate neurotransmitter systems, particularly serotonin and dopamine pathways, makes it a valuable tool for investigating the mechanisms underlying these disorders.

The synthesis of< strong>4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride involves multi-step organic reactions that require precise control over reaction conditions. The introduction of the piperazine group necessitates careful consideration of reaction pathways to ensure high yield and purity. Advances in synthetic methodologies have enabled more efficient and scalable production processes, making this compound more accessible for industrial applications.

In addition to its pharmaceutical applications, this compound has shown promise in other areas of research. Its unique chemical structure makes it a useful tool for studying enzyme inhibition and receptor binding interactions. By employing techniques such as nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography, scientists can gain insights into how< strong>4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride interacts with biological targets at a molecular level.

The< strong>CAS No. 106261-49-8 provides a unique identifier for this compound, ensuring accurate documentation and classification in scientific literature and regulatory databases. This standardized naming system facilitates communication among researchers and regulatory agencies, promoting consistency and clarity in reporting experimental results and safety data.

The future prospects for< strong>4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride are promising, with ongoing research aimed at expanding its therapeutic applications. Collaborative efforts between academic institutions and pharmaceutical companies are expected to yield novel derivatives with improved pharmacological properties. Additionally, computational modeling techniques can aid in predicting the behavior of new analogs before they are synthesized experimentally.

In conclusion, 4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride (CAS No. 106261-49-8) is a versatile compound with significant potential in pharmaceutical research and development. Its unique structural features make it an attractive scaffold for designing molecules with targeted therapeutic effects. As our understanding of biological systems continues to evolve, compounds like this will play an increasingly important role in addressing complex diseases and improving patient outcomes.

• 773109-07-2(3-((Piperazin-1-yl)methyl)benzoic Acid)
• 220213-15-0(4-\u200b(Piperazin-\u200b1-\u200bylmethyl)\u200bbenzoic Acid)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)